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INTRODUCTION
Depression is one of the most frequent disorders nowadays.
The World Health Organization (WHO) reported that 5-10% of
the general human population suffers from this disease.
Pharmacotherapy is the most important treatment method of this
disease. Recent studies on animals show that opiorphin, as a
physiological dual inhibitor of both Zn-ectopeptidases, neutral
endopeptidase and aminopeptidase N, potentiates the
enkephalinergic pathway which then induces an antidepressive-
like effect (1). However, at present, serotonin reuptake inhibitors
are the first choice drugs in depression treatment. Citalopram
belongs to one of the most commonly prescribed drugs in the
pharmacotherapy of depression (2, 3). Citalopram is a selective
serotonin reuptake inhibitor (SSRI) and, similar to other drugs
from this group, CIT is a racemic mixture of S(+) and R(–)
enantiomers. S-citalopram is a therapeutically active enantiomer.
Baumann and co-workers reported that S-citalopram is
approximately twice as potent as an inhibitor of serotonin reuptake
in comparison to citalopram, and 100-fold more potent than the R-
enantiomer (4). The S-citalopram enantiomer and its metabolites
are metabolized faster than their antipodes. The S/R ratio in the
plasma of patients after an oral dose of the drug (ratio 1:1) has
been shown as 0.56 and 0.69 for CIT and DCIT, respectively (5).
Citalopram is metabolized to desmethylcitalopram by
cytochromes CYP2C19 and CYP3A4, and to
didesmethylcitalopram (DDCIT) by cytochrome CYP2D6 (6).
An in vitro study suggested that citalopram is at least 4 times
more potent than DCIT and 13 times more potent than DDCIT
in the inhibition of serotonin reuptake, but Brosen and co-
workers reported that these two metabolites are not active (7, 8).
After a single dose of citalopram, as well as at steady state, the
concentrations of metabolites are 30–50% of DCIT and 5–10%
of DDCIT (4, 7).
Cigarette smoking is widely spread among depressive
patients. Tobacco smoke contains more than 4200 chemical
compounds (9, 10). Some tobacco smoke ingredients (e.g.,
tobacco-specific N-nitrosamines, TSNA) are metabolized by
cytochrome P-450, which is also involved in the metabolism of
citalopram (11, 12). Carbon monoxide, heavy metals and reactive
nitrogen species present in tobacco smoke can also influence
enzyme activity. The cytochrome activity changes may affect the
metabolism of citalopram (13). Thus it can be assumed that this
influence can be different for particular enantiomers of this drug.
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The purpose of this study was to evaluate the influence of tobacco smoke on the pharmacokinetics of citalopram (CIT)
and desmethylcitalopram (DCIT) and its enantiomers on an animal model. High performance liquid chromatography
(HPLC) with a diode array detector (DAD) was used for the identification and quantification of the studied compounds.
The HPLC quantification of racemic mixtures of CIT was performed on a C18 column. The limits of detection (LOD)
and quantification (LOQ) were: 7 and 10 ng/ml respectively. HPLC separation of citalopram enantiomers (S- and R-
CIT) was performed on a Chirobiotic V column. The limits of detection (LOD) and quantification (LOQ) were: 6 and
15 ng/ml for R- and S-CIT respectively. The experiment was carried out on male Wistar rats. The rats were exposed to
tobacco smoke for five days (6 hours per day). After the exposure, citalopram was administered in a dose of 10 mg/kg
intragastrically. In the control group (non-exposed animals), citalopram was administered in the same way and at an
equal dose. The blood of the animals was collected at nine time points. It was found that tobacco smoke exposure
inhibits the biotransformation of citalopram. The half-life of the racemic mixture of citalopram after intragastric
administration was increased by about 287%. Changes in the pharmacokinetic parameters of S-citalopram (active
isomer) show a similar tendency to those of the racemic mixture. The pharmacokinetics of R-citalopram showed no
statistically important differences after tobacco smoke exposure. Alterations in the pharmacological parameters of
desmethylcitalopram presented an opposite trend to the parent drug. After exposure to tobacco smoke, the induction of
metabolism of this compound was observed.
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The aim of this study was to evaluate of tobacco smoke
influence on the pharmacokinetics of citalopram enantiomers in
animal model.
MATERIAL AND METHODS
Animals
Male Wistar rats with an average body weight of 225 g bred
at the Department of Toxicology, University of Medical Sciences
(Poznan, Poland), were housed in polycarbonate cages with
hardwood chip bedding. A standard laboratory diet of Labofeed
(Feeds and Concentrates Production Plant, Certificate of Quality
System No 181/1/98, Kcynia, Poland) and water were available,
with no limitations. Throughout the entire study period, a 12/12 h
light/dark cycle was maintained. After 14 days of initial
acclimatization, the rats were randomized and divided into two
groups of 24 rats each. The protocol for this animal experiment
was approved by the Local Ethics Commission for Animal
Studies in Poznan (No.32/2008, June 20th 2008).
Group I was exposed to tobacco smoke in a dynamic
toxicological chamber for 5 days (6 hours per day). The chamber is
a glass rectangular cuboid of 308 dm3 capacity, fitted with parallel
tubing. There is a movable cover situated in the upper part and
carbon monoxide detectors located in the lateral walls of the tank.
Tobacco smoke is introduced into the chamber through a pipe,
connected to perforated tubing. The air outlet vent is located on the
opposite side. This tubing system provides an even and uniform
distribution of smoke within the chamber (14). Tobacco smoke was
generated from Polish cigarettes without a filter tip (“Poznanskie”,
20 pieces per pack, Imperial Tobacco Poland S.A.). The CO
concentration in the chamber reflected the smoke content in the
inhaled air and was continuously monitored by a gas analyzer,
Infralyt 1110/1210 (infrared measurement), to maintain 1,500 mg
CO/m3 of air. The level of oxygen was established at 20±0.5% of
the air volume. The air in the chamber was changed 10 times per
day. After exposure, citalopram (Lundbeck, Denmark) was
administered by a gavage at a dose of 10 mg/kg body weight.
Group II (control - without exposure to tobacco smoke) -
citalopram (Lundbeck, Denmark) was administered by a gavage
at a dose of 10 mg/kg body weight. After administration of
citalopram, the rats were anesthetized (a mixture of xylocaine
40 mg/kg and ketamine 5 mg/kg). Blood samples from the
jugular vein were collected into tubes without an anticoagulant
at eight time-points (0.33; 0.66; 1; 1.5; 2; 4; 8; 24 h) with three
rats per point. The serum was subsequently separated by
centrifugation for further analysis.
Citalopram and desmethylcitalopram measurement
For the determination and quantification of citalopram and its
main metabolite (desmethylcitalopram), high performance liquid
chromatography with a diode array detector was used. The analytes
were isolated from the plasma by liquid-liquid extraction with the
use of n-hexane and isoamyl alcohol mixture (98.5: 1.5 v/v). The
HPLC separation of CIT and DCIT was performed on a C18
column (Spheri-5, 100×4.5 mm, 5 µm diameter), using a mixture
of diluted solution of phosphoric (V) acid with an addition of 1%
diethylamine at pH 2.36 and acetonitrile (40 : 60 (v/v)) as a mobile
phase. The validation parameters are presented in Table 1.
Enantiomers of citalopram and desmethylcitalopram
measurement
For the determination and quantification of enantiomers of
citalopram (R-CIT and S-CIT) and its main metabolite (R-DCIT
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Parameter Citalopram Desmethylcitalopram 
Linearity [ng/ml] 10–500 10–300 
Slope of calibration curve, a 0.0052 0.0038 
Intercept, b -0.047 0.018
Correlation coefficient, R2 0.9990 0.9984
LOD [ng/ml]  7 8 
LOQ [ng/ml] 10 10 
Precision of retention time, (n=5), 
RSD% 0.2 0.2
Intra-day precision at 75 ng/ml, 
(n=4), RSD% 12.4 10.3
Intra-day precision at 500 ng/ml
(CIT) and at 300 ng/ml (DCIT), 
(n=4), RSD% 
11.9 8.0
Inter-day precision at 75 ng/ml, 
(n=4), RSD% 10.7 15.4
Inter-day precision at 500 ng/ml
(CIT) and at 300 ng/ml (DCIT), 
(n=4), RSD% 
11.3 16.0
Accuracy at 75 ng/ml (n=4), 
relative error [%] 2.6 10.5
Accuracy AT 500 ng/ml (CIT)
and at 300 ng/ml (DCIT),
(n=4), relative error [%]
29.7 18.8
Efficiency of extraction at 
75 ng/ml, (n=4) 89.25 73.43
Efficiency of extraction at 
500 ng/ml (CIT) and at 300 ng/ml 
(DCIT), (n=4)
86.64 70.96
Table 1. Validation parameters of determination of citalopram and desmethylcitalopram in plasma.
and S-DCIT), HPLC-DAD was used. The separation of analytes
from the plasma was achieved by liquid-liquid extraction with
the use of an n-hexane and isoamyl alcohol mixture (98.5: 1.5
v/v). The HPLC separation of enantiomers of citalopram and
desmethylcitalopram was performed with a modified method of
Kosel and co-workers (15) on a Chirobiotic V column (250×4.5
mm and 5 µm diameter) purchased from Aldrich, Germany.
Elution was performed with a mixture of methanol: acetic acid :
triethylamine (99.9: 0.055: 0.060 v/v). The limits of detection
and quantification are presented in Table 2.
Statistical and pharmacokinetic analysis
The pharmacokinetic analysis of citalopram,
desmethylcitalopram and its enantiomers was carried out by the
model-independent method (statistical moment analysis) using
the SPLINE computer program.
The following parameters were calculated: the area under
the plasma concentration time curve (AUC), the area under the
first moment curve (AUMC), the mean resident time (MRT), the
elimination rate constant (k), the biological half-life (t0.5), the
total clearance (Cls) and the volume of distribution (Vd).
The t-Student’s test was used to assess the statistical
significance of differences between the mean values of
individual parameters in both the tobacco smoke exposed and
non-exposed groups. In the calculations of probability
distribution, a single track and 95% confidence interval were
assumed (α=0.05).
RESULTS
The experiment was performed on two groups of Wistar
rats. The first group was exposed to tobacco smoke for five days
(6 hours per day). After exposure they were administered
citalopram by a gavage at a dose of 10 mg/kg. The second
(control) group of rats was given citalopram in the same way
and dose, although it was not exposed to tobacco smoke. The
time profile of citalopram and desmethylcitalopram
concentration is presented in Fig. 1.
Changes in concentrations of citalopram enantiomers and
desmethylcitalopram depending on the time elapsed from drug
administration are presented in Fig. 2 and 3, respectively.
Between the two studied groups, particular parameters were
compared - the area under the plasma concentration time curve
(AUC), the area under the first moment curve (AUMC), the
mean time of residence (MRT), the elimination rate constant (k),
the half-life of the drug (t0.5), the total clearance (Cls) and the
volume of distribution (Vd). The results are summarized in Table
3 and 4.
DISCUSSION
In the present study, the influence of tobacco smoke on the
pharmacokinetics of citalopram and desmethylcitalopram and its
enantiomers has been investigated. In the animal model
experiment, two groups of rats were formed. The first group was
exposed to tobacco smoke for five days (6 hours per day). After
the exposure, 10 mg/kg of citalopram was administered
intragastrically. The second group (control) received citalopram
in the same way and at an equal dose, although there was no
exposure to tobacco smoke. Generally there are no significant
differences between altering the concentrations of citalopram
and its metabolite determined in the plasma of rats exposed to
tobacco smoke and in the control group (Fig. 1). However, the
slope of the concentration-time curve suggests that the
elimination of the drug in the control group was more rapid.
As for the enantiomers of citalopram, it was observed that
the S-isomer was eliminated much faster in the group exposed to
tobacco smoke than in the control group (Fig. 2B). Faster
metabolism and a higher first past effect associated with it
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Parametr R–CIT S–CIT R–DCIT S–DCIT 
Linearity [ng/ml] 15–500 15–500 15–500 15–500 
Slope of calibration curve, a 0.0400 0.0442 0.0345 0.0313 
Intercept, b -0.2713 0.1917 -0.2513 -0.4604
Correlation coefficient, R2 0.9937 0.9913 0.9977 0.9919
LOD [ng/ml] 6 6 4 7 
LOQ [ng/ml] 15 15 15 15 
Precision of retention time, (n=5). 
RSD% 0.2 0.2 0.2 0.2
Intra-day precision at 25 ng/ml, 
(n=4). RSD% 2.2 4.7 2.2 3.7
Intra-day precision at 200 ng/ml, 
(n=4). RSD% 7.3 5.4 3.5 1.8
Inter-day precision at 25 ng/ml, 
(n=4). RSD% 8.9 21.0 4.3 7.9
Inter-day precision at 200 ng/ml. 
(n=4). RSD% 5.9 21.3 3.5 11.5
Accuracy at 25 ng/ml (n=4). 
relative error [%] 0.9 24.9 0.9 24.8
Accuracy at 200 ng/ml. (n=4). 
relative error [%] 20.7 11.7 15.2 3.9
Efficiency of extraction at 
25 ng/ml. (n=4) 87.05 54.01 60.27 63.24
Efficiency of extraction at 
200 ng/ml. (n=4) 82.31 73.21 63.04 66.37
Table 2. Validation parameters of determination of R- and S-citalopram and R- and S-desmethylcitalopram in plasma.
resulted in a lower concentration of S-enantiomer (Fig. 2B)
when compared to the racemic mixture (Fig. 1A) and a much
lower one in comparison to R-enantiomer (Fig. 2A). A similar
tendency was previously observed in the racemic mixture of
citalopram, for which the change was not as significant as in the
case of S-citalopram. This phenomenon can be explained by the
lack of changes in the R-citalopram elimination rate (Fig. 2A).
The opposite tendency can be observed in the metabolite of
citalopram. R-desmethylcitalopram showed no changes after
tobacco exposure, while S-isomer persisted longer in the bodies
of unexposed animals (Fig. 3).
Statistically significant changes were found for all of the
pharmacokinetic parameters of citalopram racemic mixture
between the group of exposed animals and the control group
(Table 3). The half-life of the racemic mixture of citalopram,
following intragastric application, increased by about 287%. As
a consequence, the area under the citalopram concentration time
curve (AUC) determined in the plasma samples of the exposed
animals increased by almost 100%. Alterations in the
biotransformation of citalopram may be the underlying cause of
this situation. Citalopram is metabolized mainly by CYP2D6,
CYP2C19 and CYP3A4 isoenzymes (5, 7). Additionally,
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Fig. 1. Time profile of citalopram (A) and desmethylcitalopram
(B) concentration in plasma of rats after intragastric
administration of citalopram in dose 10 mg/kg.
Fig. 2. Time profile of R-citalopram (A) and S-citalopram (B)
concentration in plasma of rats after intragastric administration
of citalopram in dose 10 mg/kg.
Parameter AUC[µg·h/l] %
AUMC
[µg·h2/l] %
Cls
[l/h·kg] %
Vd
[l/kg] %
MRT
[h] %
t0.5 
[h] %
C 204.1±58.9 426.9±174.6 52.0±15.8 103.2±16.9 2.04±0.3 1.20±0.1 CIT
E 390.5±102.1* 
91
2689.5±957.0* 
530
26.9±7.7* 
48
177.8±28.4* 
72
6.75±0.8* 
231
4.64±0.8* 
287
C 267.0±38.7 1899.4±1163.0 19.0±2.3 134.6±77.2 7.12 ±4.2 3.09±0.2 R-CIT
E 355.7±76.5 
33
2231.3±824.9 
17
14.5±3.3 
24
86.6±3.9 
35
6.12±1.2 
14
4.02±0.9 
30
C 21.1±6.6 31.94±17.0 256.6±96.1 354.3±81.5 1.45±0.4 0.63±0.5 S-CIT
E 24.6±9.8 
16
77.5±57.4 
142
226.2±87.2 
12
603.7±94.3* 
70
2.90±1.0* 
100
2.12±0.9* 
236
C - control group; E - cxposure group; % - percentage change of parameter exposed group compared to the control group; 
* - statistically significant difference assuming significant level p equal to 95% (α=0.05).
Table 3. Pharmacokinetic parameters of racemic mixture of citalopram and its enantiomers designated in the group of exposure to
tobacco smoke and in the control group. Animals of both groups were given citalopram intragastrically at a dose 10 mg/kg.
according to Kobayashi and co-workers, CYP3D4 is the most
active factor in the N-demethylation of citalopram in the human
liver (16), which is contrary to the result by Sindrup and co-
workers, who suggested that the major isoensyme in this process
is CYP2C19 (17).
Isoforms of enzymes CYP2D6 and CYP3A4 also participate in
the biotransformation process of tobacco-specific N-nitrosamines
(NAST) (11). During the simultaneous biotransformation of
citalopram and NAST, competition for the active site of enzymes
may occur between them. The result may slow down the
biotransformation of the drug.
Changes in the pharmacokinetic parameters of S-
citalopram (active isomer) show a similar tendency to those of
the racemic mixture. Under the influence of tobacco smoke, the
changes in the mean time of residence and half-time of S-
citalopram were extended by about 100% and 236%
respectively. There were no statistically important differences
between these pharmacokinetic parameters for R-citalopram in
the studied group.
Changes in the pharmacokinetic parameters of
desmethylcitalopram represented a tendency opposite to the
parent compound (Table 4). After exposure to tobacco smoke,
the MRT and the biological half-life decreased substantially.
Desmethylcitalopram is metabolized further to
didesmethylcitalopram only by CYP2D6, which is also involved
in the biotransformation of NAST. It is assumed that prolonged
exposure of this cytochrome to these xenobiotics can lead to its
induction and thus to an increase in the elimination of
desmethylcitalopram.
For both S-desmethylcitalopram and the racemic mixture of
the compound, inhibition of the biotransformation was observed,
whereas the changes of R-desmethylcitalopram were of no
statistical importance.
It can be concluded that the elimination rate of citalopram is
decreased after tobacco smoke exposure due to inhibition of the
S-enantiomer elimination, whereas the R-citalopram elimination
rate remains constant.
In the case of the metabolite of citalopram, the changes
observed were in the opposite direction to those described for the
parent drug. It was determined that tobacco smoke exposure
induces the biotransformation processes of the
desmethylcitalopram racemic mixture. Additionally, a similar
effect occurred under the influence of tobacco smoke in the S-
enantiomer. The R-isomer, on the other hand, showed no
statistically significant differences.
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